

AGENDA
 AREA DRUG AND THERAPEUTICS COMMITTEE
 WEDNESDAY 15th March 2023 @10am
 Microsoft Teams Meeting

		Action
1.	<p><u>Apologies for Absence</u> David Semple Penny Brankin Gail Richardson</p> <p><u>In Attendance</u> Mehrdad Malekian (MM) Chair Victoria Gemmell (VG) Minutes Stephanie Dundas (SD) Christine Gilmour (CG) Carol McGoff (CM) Tyra Smyth (TS) Emma Harris (EH) Mark Kirk (from item 7)</p>	
2.	<p><u>Declaration of Interest</u> <u>nil</u></p>	
3.	<p><u>Matters arising not covered elsewhere on the agenda</u></p> <p>a. <u>Ratification of minutes of meeting 15th February 2023</u> The minutes were accepted as true records and can now be published</p> <p>b. <u>Dermatology Update</u> Final versions for saving. Previously agreed</p> <p>c. <u>Utrogestan update</u> Carried over to April meeting-revised documents awaited</p> <p>d. <u>Roxadustat</u> No additional comments. Accepted for use</p> <p>e. <u>Ulcerative Colitis Pathway</u> No additional comments. Accepted for use</p>	

<p>f.</p> <p>g.</p> <p>h.</p> <p>i.</p>	<p><u>Covert Medication Pathway</u></p> <p>Some further comments</p> <ul style="list-style-type: none"> • Pg 3-AWIA and MHA are both referenced. Further information is given on AWIA but not on MHA. Clarify where/when MHA may be necessary and how it relates to covert medication. • Consulting Others paragraph-move to after next section. • Supporting documentation-add links to facilitate access <p><u>ADTC TOR review – Update</u></p> <p>Updated version will be worked up and presented at a later date</p> <p><u>Status Epilepticus</u></p> <p>No additional comments. Accepted for use Both Form C’s completed</p> <p><u>Estradiol (Combined HRT) – Update</u></p> <p>Carried over to April meeting-revised documents awaited</p>	<p>VG</p> <p>MM/VG</p>
<p>4.</p>	<p><u>SMC Advice</u> CONFIDENTIAL</p> <p>Please see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website after 2.00 pm on Monday 10 April 2023.</p> <p><u>FULL SUBMISSIONS</u></p> <ul style="list-style-type: none"> • darolutamide 300mg film-coated tablets (Nubeqa) Bayer plc treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel SMC2544 NOT RECOMMENDED FOR NOTING • trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu) Daiichi Sankyo UK Ltd SMC2545 as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. ACCEPTED RESTRICTED WITH PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance. 	

	<p><u>Update on the interim assessment approach in response to COVID-19</u></p> <p>This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for two medicines, one full, and on abbreviated submission will be issued in confidence to NHS Boards on Friday 10 March, and published on the SMC website on Monday 10 April 2023.</p> <p><u>FULL SUBMISSION</u></p> <ul style="list-style-type: none"> • pembrolizumab concentrate for solution for infusion (Keytruda) (Melanoma) Merck Sharp & Dohme (UK) Ltd SMC2526 as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection ACCEPTED WITH PAS FOR NOTING- The West of Scotland Cancer Network (WoSCAN) will provide guidance. <p><u>ABBREVIATED SUBMISSION</u></p> <ul style="list-style-type: none"> • patiomer sorbitex calcium 8.4mg and 16.8mg powder for oral suspension (Veltassa) Vifor Fresenius Medical Care Renal Pharma UK Ltd SMC2568 ACCEPTED RESTRICTED To be reviewed by Renal and Biochemistry <p><u>FOR INFORMATION</u></p> <p><u>Change to licensed indication for follitropin (Pergoveris) SMC 444/08</u></p> <p>The licensed indication for follitropin alfa / lutropin alfa (Pergoveris) has been altered by removal of the statement: ‘In clinical trials, these patients were defined by an endogenous serum LH level <1.2 IU/L’. SMC considers this a minor change. No further update will be provided.</p> <p><u>Paediatric Licence Extensions</u></p> <p>FOR NOTING</p>	<p>CM</p>
<p>5.</p>	<p><u>SMC follow up</u></p> <p>CM talked the Committee through the SMC follow up which had been previously circulated. Feedback on nintedanib was provided; the bulletin will be updated to ‘available in line with local or regional guidance.’</p> <p>MM will work with CM and VG with regard to templates to be sent to clinicians for SMC follow up requests to ensure all medicines have a decision.</p>	<p>CM/MM /VG</p>

	<p>6. <u>Lanarkshire Formulary</u> CM proposed updating the Lanarkshire formulary website to reflect the change in the recommended brand of fentanyl patch in primary care from Matrifen® to Mezolar Matrix® due to stock shortages.</p> <p>The Committee accepted this proposal.</p> <p>7. <u>Clinical Protocols</u></p> <p>(a) <u>Vabysmo DMO and Vabysmo nAMD</u></p> <p>No additional comments. Both clinical protocols accepted for use</p>	CM
	<p>8. <u>ADTC New Medicines Decisions</u></p> <p>The February 2023 New Medicines Decisions were noted.</p> <p>The August 2019 New Medicines Decisions were updated to reflect local advice for SMC2167 tildrakizumab (Ilumetri®).</p> <p>The November 2021 New Medicines Decisions were updated to reflect local advice for SMC2410 bimekizumab (Bimzelx®).</p> <p>The April 2022 New Medicines Decisions were updated to reflect local advice on SMC2417 upadacitinib (Rinvoq®) and WoSCAN advice on SMC2412 venetoclax (Venclyxto®).</p> <p>The June 2022 New Medicines Decisions were updated to reflect local advice on SMC2431 abrocitinib (Cibinqo®).</p> <p>The November 2022 New Medicines Decisions were updated to reflect local advice on SMC2477 belimumab (Benlysta®) and SMC2530 belimumab (Benlysta®) and national guidance on SMC2123 Buprenorphine/naloxone (Zubsolv®).</p>	
	<p>9. <u>Unlicensed Medicines</u></p> <p><u>nil</u></p>	
	<p>10. <u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p> <p>Nil</p>	
	<p>11. <u>Regional Cancer Advisory Network</u></p> <p>Nil</p>	

12	<p><u>Patient Safety Alerts</u> Nil</p>	
13.	<p><u>Lay member related items</u> Nil</p>	
14.	<p><u>Correspondence</u></p> <p>(i) <u>(ADTC) Collaborative</u></p> <p>a. HEPMA Vitamin D Process</p> <ul style="list-style-type: none"> Concerns raised due to the use of HEPMA (potential system and user error) when prescribing Vitamin D and zoledronic acid. <p>ACTION: ensure that there is a robust process for confirming the <u>administration</u> of high-dose Vit D at least 48 hours in advance of iv zoledronic acid.</p> <p>VG to liaise with HEPMA lead to confirm they are aware</p> <p>b. ScotCap Guidelines</p> <p>This is a National program, however due to the use of off-label prucalopride, Boards are asked to review and confirm their agreement. Group can send any further comments by email which will be collated. CG is current point of contact and will feedback to the national co-ordinator</p> <p>c. HCSW Medication Admin Framework</p> <p>CG to take this forward with nursing colleagues TS will also provide feedback to CG</p> <p>d. ADTCC Forum</p> <p>VG gave an update on topics discussed Yellow Card reporting-numbers for NHSL remain low compared to other Boards. Suggested an item in Prescribing Notes for Primary Care colleagues and to find out more about a possible HEPMA app that facilitates easy reporting</p>	<p>VG</p> <p>CG</p> <p>CG</p> <p>VG</p>
15.	<p><u>Pharmacy & NMAHP Prescribing Governance</u> Nil</p>	
16.	<p><u>AOCB</u> Nil</p>	

17.	<u>Date of next meeting</u> 19 th April 2023 @ Microsoft Teams 10am	
-----	--	--